三阴性乳腺癌的化疗敏感性与化疗耐药性：生物标志物识别的当前进展
Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification.
作者信息
Guestini Fouzia, McNamara Keely May, Ishida Takanori, Sasano Hironobu
机构信息
a Department of Anatomic Pathology , Tohoku University School of Medicine , Aoba-ku, Sendai , Japan.
b Department of Surgical Oncology , Tohoku University Graduate School of Medicine , Aoba-ku , Sendai , Japan.
出版信息
Expert Opin Ther Targets. 2016 Jun;20(6):705-20. doi: 10.1517/14728222.2016.1125469. Epub 2015 Dec 19.
INTRODUCTION
Triple negative breast cancer (TNBC) is a heterogeneous clinicopathological entity constituting approximately 15 - 20% of all breast cancer (BC) patients. It shows high recurrence rate and poor prognosis. At this juncture, because of the lack of specific targeted therapies available and the development in patients of resistance to some therapeutic agents, clinical and translational settings have gained importance over the past decades.
AREAS COVERED
The development of novel, safe and effective alternatives for the treatment of TNBC are in high demand. Therefore, this review aims to summarize the state of the art of TNBC, its current therapies and potential therapeutic targets. In particular, focus is put on recent advances regarding the identification of emerging biomarkers as prognostic and/or predictive markers, including surrogate markers for molecular tumor subtyping and identifying potential responders to new therapies.
EXPERT OPINION
Effective development of informative markers could constitute an important armamentarium tool for identifying appropriate therapies to challenge the aggressiveness of TNBC.
引言
三阴性乳腺癌（TNBC）是一种异质性的临床病理实体，约占所有乳腺癌（BC）患者的15%-20%。它显示出高复发率和不良预后。在这个关头，由于缺乏可用的特异性靶向治疗方法以及患者对某些治疗药物产生耐药性，在过去几十年中，临床和转化研究变得至关重要。
涵盖领域
对于治疗TNBC的新型、安全且有效的替代方案有很高的需求。因此，本综述旨在总结TNBC的最新进展、其当前的治疗方法以及潜在的治疗靶点。特别关注在鉴定新兴生物标志物作为预后和/或预测标志物方面的最新进展，包括用于分子肿瘤亚型分类的替代标志物以及识别对新疗法的潜在反应者。
专家观点
有效开发信息性标志物可能构成一种重要的武器库工具，用于识别合适的疗法以应对TNBC的侵袭性。
Zotero 插件